About Tony Wood

Tony Wood is Chief Scientific Officer at GlaxoSmithKline.
He has a BSc in chemistry and a PhD in organic synthesis from Newcastle University. After a postdoc at
Imperial College, he spent 25 years with Pfizer in the UK and the US, before moving to his current role at
GSK in 2017.

He is one of the world’s pre-eminent medicinal chemists, and has the rare distinction of inventing a
licensed medicine, the HIV antiviral maraviroc (Celsentri/Selzentry). This was the first mammalian host
protein-targeted anti-HIV drug to reach the market. As well as being a pioneer of structure-based drug
design to overcome problems of resistance, he has striven to advance strategies in medicinal chemistry
design, including ligand efficiency and lipophilic efficiency, structural-property relationships for toxicity,
and the use of chemoinformatics to inform molecule and library design.

Dr Wood has received several awards for maraviroc, including the PhRMA Discoverers Award, the Prix
Galien USA and the ACS Heroes of Chemistry Award. He was also the recipient of the 2005 Malcolm
Campbell Award for Medicinal Chemistry from the Royal Society of Chemistry, and the 2010 UCB Ehrlich
Award for Medicinal Chemistry from the European Federation of Medicinal Chemistry.

He is a Fellow of the Academy of Medical Sciences and a Fellow of the Royal Society of Chemistry.